CME Group Inc. (CME) Stake Decreased by Exane Derivatives

Exane Derivatives lessened its stake in shares of CME Group Inc. (NASDAQ:CME) by 7.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,235 shares of the financial services provider’s stock after selling 419 shares during the quarter. Exane Derivatives’ holdings in CME Group were worth $710,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of CME. Fiduciary Trust Co. purchased a new stake in shares of CME Group during the 2nd quarter worth approximately $105,000. Quadrant Capital Group LLC lifted its position in shares of CME Group by 13.6% during the 2nd quarter. Quadrant Capital Group LLC now owns 944 shares of the financial services provider’s stock worth $111,000 after buying an additional 113 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of CME Group by 4.1% during the 1st quarter. Parallel Advisors LLC now owns 1,084 shares of the financial services provider’s stock worth $128,000 after buying an additional 43 shares during the last quarter. San Francisco Sentry Investment Group CA purchased a new stake in shares of CME Group during the 2nd quarter worth approximately $129,000. Finally, Whittier Trust Co. lifted its position in shares of CME Group by 2.6% during the 2nd quarter. Whittier Trust Co. now owns 1,057 shares of the financial services provider’s stock worth $133,000 after buying an additional 27 shares during the last quarter. Institutional investors and hedge funds own 82.62% of the company’s stock.

Several analysts have recently weighed in on the stock. Royal Bank Of Canada boosted their price objective on shares of CME Group from $135.00 to $147.00 and gave the stock an “outperform” rating in a research report on Monday, October 16th. BidaskClub cut shares of CME Group from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Citigroup Inc. lifted their target price on shares of CME Group from $138.00 to $155.00 and gave the company a “buy” rating in a report on Thursday. Keefe, Bruyette & Woods reaffirmed a “hold” rating and issued a $127.00 target price on shares of CME Group in a report on Friday, August 18th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $128.00 target price on shares of CME Group in a report on Monday, July 10th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $138.89.

In other CME Group news, CFO John W. Pietrowicz sold 2,500 shares of the stock in a transaction on Wednesday, October 11th. The stock was sold at an average price of $136.83, for a total value of $342,075.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Chairman Terrence A. Duffy sold 21,815 shares of the stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $123.89, for a total value of $2,702,660.35. Following the completion of the sale, the chairman now directly owns 110,711 shares in the company, valued at $13,715,985.79. The disclosure for this sale can be found here. Insiders have sold 49,594 shares of company stock worth $6,239,015 over the last 90 days. 0.57% of the stock is currently owned by company insiders.

Shares of CME Group Inc. (CME) traded up 0.13% during trading on Friday, hitting $135.13. 1,180,139 shares of the stock were exchanged. The company has a market cap of $45.93 billion, a price-to-earnings ratio of 27.58 and a beta of 0.73. CME Group Inc. has a 12-month low of $98.95 and a 12-month high of $138.49. The firm has a 50 day moving average of $133.68 and a 200-day moving average of $124.49.

CME Group (NASDAQ:CME) last announced its quarterly earnings data on Tuesday, August 1st. The financial services provider reported $1.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.20 by $0.03. CME Group had a return on equity of 7.61% and a net margin of 46.05%. The firm had revenue of $925.00 million for the quarter, compared to analysts’ expectations of $931.05 million. During the same period last year, the business posted $1.14 earnings per share. The firm’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, analysts forecast that CME Group Inc. will post $4.81 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 25th. Investors of record on Friday, September 8th were paid a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a yield of 1.95%. The ex-dividend date was Thursday, September 7th. CME Group’s dividend payout ratio (DPR) is presently 53.99%.

ILLEGAL ACTIVITY NOTICE: “CME Group Inc. (CME) Stake Decreased by Exane Derivatives” was published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.themarketsdaily.com/2017/10/22/cme-group-inc-cme-stake-decreased-by-exane-derivatives.html.

About CME Group

CME Group Inc, through its exchanges, provides products across all asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products and metals. The Company’s segment primarily consists of the Chicago Mercantile Exchange Inc (CME), Board of Trade of the City of Chicago, Inc (CBOT), New York Mercantile Exchange, Inc (NYMEX) and Commodity Exchange, Inc (COMEX) exchanges.

Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CME).

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply